Quick summary
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide matrikine that stimulates fibroblast synthesis of collagen I, III, glycosaminoglycans, and elastin. It is a key component of the Matrixyl 3000 system and has shown 39% reduction in wrinkle length in clinical studies after 4 weeks.
Overview
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide consisting of the tripeptide sequence Gly-His-Lys conjugated to a palmitic acid chain. It is a structural analog of GHK (the copper-binding tripeptide) but without copper coordination, functioning instead as a matrikine signal peptide. It stimulates fibroblast synthesis of collagen I and III, glycosaminoglycans, and elastin, and is widely used in professional anti-aging skincare formulations, often combined with Palmitoyl Tetrapeptide-7 in the Matrixyl 3000 ingredient system.
Mechanism of action
Palmitoyl Tripeptide-1 functions as a matrikine — a peptide fragment derived from ECM protein degradation that signals fibroblasts to upregulate matrix synthesis. The GHK sequence binds fibroblast surface receptors and activates intracellular TGF-β pathway components and downstream collagen gene transcription (COL1A1, COL3A1). The palmitoyl fatty acid chain increases the molecule's lipophilicity, enabling penetration through the stratum corneum into the viable epidermis and dermis. In vitro studies confirm stimulation of collagen I, III, and glycosaminoglycan synthesis at sub-micromolar concentrations. It has also been shown to modulate MMP expression, reducing collagen degradation in UV-aged skin models.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| collagen stimulation and anti-aging | topical | 2–5 % | twice daily | Effective at 0.5–3 ppm pure peptide in finished formulation. Apply to face and neck. Results typically visible after 4–8 weeks of consistent use. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Clinical studies demonstrate measurable improvements in periorbital wrinkle depth and length with twice-daily application of creams containing Palmitoyl Tripeptide-1 at concentrations of approximately 3 ppm. A 4-week eye zone study found 39% reduction in wrinkle length, 23% reduction in wrinkle depth, and 17% reduction in overall skin roughness versus vehicle. The CIR Expert Panel has assessed Palmitoyl Tripeptide-1 as safe for cosmetic use. It is a primary component of the Matrixyl 3000 system alongside Palmitoyl Tetrapeptide-7.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Palmitoyl Tripeptide-1 for synergistic effects.
Legal status
Permitted cosmetic ingredient in the US, EU, and most global markets. Regulated as a cosmetic; no prescription or drug approval required. Sold as a raw ingredient for cosmetic formulators and in finished OTC skincare products.
Sourcing & access
Research compound
Palmitoyl Tripeptide-1 is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide consisting of the GHK tripeptide conjugated to palmitic acid. It functions as a matrikine signal peptide that stimulates collagen and elastin production and is a primary component of the Matrixyl 3000 anti-aging system.
The GHK sequence binds fibroblast surface receptors and activates the TGF-beta pathway, upregulating collagen I and III gene transcription. The palmitoyl chain increases lipophilicity for better skin penetration. It also modulates MMP expression, reducing collagen degradation in UV-aged skin.
It is generally very well tolerated. The CIR Expert Panel has assessed it as safe for cosmetic use. Mild skin irritation in sensitive individuals is rare, and no systemic effects are expected at cosmetic concentrations.
Clinical studies show 39% reduction in wrinkle length, 23% reduction in wrinkle depth, and 17% reduction in skin roughness after 4 weeks of twice-daily application. Results are typically visible after 4 to 8 weeks of consistent use.
Research references
- Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospectivePubMed
- Topical palmitoyl pentapeptide provides improvement in photoaged human facial skinPubMed
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin RegenerationPubMed
- Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+PubMed